Gritstone bio, Inc. (GRTS)

Market Cap	86.79M
Revenue (ttm)	16.34M
Net Income (ttm)	-138.49M
Shares Out	106.40M
EPS (ttm)	-1.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	594,254
Open	0.758
Previous Close	0.765
Day's Range	0.758 - 0.817
52-Week Range	0.670 - 3.330
Beta	0.43
Analysts	Strong Buy
Price Target	6.33 (+674.98%)
Earnings Date	May 9, 2024

About GRTS

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatme...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 28, 2018
• Employees: 231
• Stock Exchange: NASDAQ
• Ticker Symbol: GRTS

Financial Performance

In 2023, Gritstone bio's revenue was $16.34 million, a decrease of -18.05% compared to the previous year's $19.95 million. Losses were -$138.49 million, 15.7% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for GRTS stock is "Strong Buy." The 12-month stock price forecast is $6.33, which is an increase of 674.98% from the latest price.

Price Target

$6.33

(674.98% upside)

Analyst Consensus: Strong Buy